Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of May 2022, with a specific transaction date of May 23, 2022. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific securities transaction:
- Instrument: American Depositary Shares (ADSs)
- Transaction Type: Acquisition within an Executive Supplemental Savings Plan
- Price: $44.7500 per ADS
- Volume: 1,151.020 ADSs
- Exchange: New York Stock Exchange (XNYS)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an insider transaction involving Dr. H Barron, Chief Scientific Officer and President, R&D.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance notification for a specific executive trade.
Key Facts for Investor Verification
- Dr. H Barron acquired 1,151.020 GSK ADSs at $44.75 on May 23, 2022.
- The transaction was executed via the GSK Executive Supplemental Savings Plan.
- This filing does not contain quarterly or annual financial performance data.